2. Disease Areas
  3. Metabolic or Endocrine Disease
  4. Lipid Metabolism

Lipid Metabolism

Disorders of lipid metabolism, also known as dyslipidemia, involve abnormal levels of lipids in the blood, including elevated triglycerides and low-density lipoprotein (LDL), and reduced high-density lipoprotein (HDL), leading to conditions such as pancreatitis, atherosclerosis, and coronary artery disease. These disorders arise from genetic defects in enzymes or transport proteins involved in fatty acid oxidation and lipid processing, resulting in impaired lipid metabolism and toxic accumulation of lipids in tissues like the liver, brain, and bone marrow. They are classified as inborn errors of metabolism, with some forms presenting as metabolic myopathy. Key genes implicated include LIPC, associated with hepatic lipase activity, and pathways involving lipid and cation transport. Conditions such as hyperlipoproteinemia type III and familial hypobetalipoproteinemia are linked to these disorders. Management may include enzyme replacement therapy for specific cases, while lifestyle modifications and medications like Pitavastatin and Valsartan are used to control lipid levels. Newborn screening and genetic testing play crucial roles in early detection and carrier identification.

 

Lipid Metabolism (2):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17386
    Rosiglitazone 122320-73-4 99.94%
    Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer.
    Rosiglitazone
  • HY-N0385
    Gomisin J 66280-25-9 99.97%
    Gomisin J is a Schisandra chinensis-derived lignan that can inhibit multiple targets such as eNOS, AMPK (LKB1, CaMKIIβ), fetuin-A, NF-κB, Nrf2/HO-1, and can pass through the blood-brain barrier. Gomisin J increases NO bioavailability by activating eNOS, regulates lipid metabolism by activating the AMPK pathway, inhibits fetuin-A and NF-κB to exert anti-inflammatory effects, and activates Nrf2/HO-1 to enhance antioxidant capacity. Gomisin J has the activities of anti-hypertension, regulating liver lipid metabolism, and reducing cerebral ischemia-reperfusion injury, and can be used for research on hypertension, non-alcoholic fatty liver disease, cerebral ischemia-reperfusion injury, etc.
    Gomisin J